表紙
市場調查報告書

纖維肌痛 : 開發平台分析

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 232816
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
纖維肌痛 : 開發平台分析 Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 131 Pages
簡介

纖維肌痛會造成肌肉骨骼系統大範圍疼痛。主要的症狀有倦怠感,頭痛,下腹部疼痛等。這個疾病的原因有遺傳要素,類風濕性關節炎,狼瘡等。

本報告提供纖維肌痛治療藥的開發情形的相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

纖維肌痛概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

纖維肌痛:企業開發中的治療藥

大學/機關研究中的治療藥

纖維肌痛:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

纖維肌痛:企業開發中的產品

大學/機關研究中的產品

纖維肌痛治療藥的開發企業

  • 第一三共
  • Intellipharmaceutics International Inc.
  • Merck & Co., Inc.
  • SWITCH Biotech LLC
  • Tonix Pharmaceuticals Holding Corp.
  • Zynerba Pharmaceuticals, Inc.

纖維肌痛:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • mirogabalin besylate
  • mirtazapine ODT
  • naltrexone hydrochloride
  • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia
  • pregabalin XR
  • Small Molecules for Fibromyalgia
  • SWT-06101
  • TD-9855
  • TNX-102
  • ZYN-001

纖維肌痛:最近的開發平台趨勢

纖維肌痛:暫停中的計劃

纖維肌痛:開發中止的產品

纖維肌痛:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12357IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H2 2020, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 8, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Fibromyalgia (Fibromyalgia Syndrome) - Overview
  • Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
  • Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
  • Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
  • Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects
  • Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products
  • Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cortene Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cytocom Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Epitech Group SpA, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Imbrium Therapeutics LP, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Innovative Med Concepts LLC, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Intec Pharma Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by NeuroCycle Therapeutics Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Pfizer Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Reven Pharmaceuticals Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020